Clinitech Laboratory Ltd
Clinitech Laboratory Ltd (CTLLAB) last reported results for the quarter ended Mar 2026, with sales of ₹4.41 crore and net profit of ₹0.12 crore. The stock last traded at ₹33.6, a market capitalisation of ₹7.68 crore, on a P/E of 18.3. Over the past 52 weeks the stock has ranged between ₹28.6 and ₹47.2. Figures are as of 6 Oct 2026 and are not real time.
Clinitech Laboratory Ltd share price and key metrics
- Current price
- ₹33.6
- Market cap
- ₹7.68 cr
- Stock P/E
- 18.3
- Book value
- ₹40.5
- ROE
- 4.65%
- ROCE
- 7.20%
- Dividend yield
- 0.00%
- 52w high / low
- 47.2/28.6
Metrics as of 6 Oct 2026. Not real time.
Track Clinitech Laboratory Ltd
Cruxal reads every Clinitech Laboratory Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Clinitech Laboratory Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 15%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 40%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- -23%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 5%
Clinitech Laboratory Ltd quarterly results
| ₹ crore | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 4.16 | 5.08 | 4.41 |
| Expenses | 3.88 | 4.54 | 3.96 |
| Operating profit | 0.28 | 0.54 | 0.45 |
| OPM % | 6.73% | 10.63% | 10.20% |
| Other income | 0.17 | 0.11 | 0.08 |
| Interest | 0.02 | 0.05 | 0.02 |
| Depreciation | 0.14 | 0.25 | 0.26 |
| Profit before tax | 0.29 | 0.35 | 0.25 |
| Tax % | 41.38% | 14.29% | 52.00% |
| Net profit | 0.17 | 0.3 | 0.12 |
| EPS (₹) | 0.74 | 1.31 | 0.53 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Clinitech Laboratory Ltd annual results
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 8.23 | 9.49 |
| Operating profit | 0.83 | 0.99 |
| OPM % | 10.09% | 10.43% |
| Net profit | 0.39 | 0.42 |
| EPS (₹) | 1.71 | 1.84 |
TTM is the trailing twelve months to the most recent quarter.
Clinitech Laboratory Ltd balance sheet
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 2.28 | 2.28 |
| Reserves | 6.55 | 6.97 |
| Borrowings | 0.00 | 0.54 |
| Other liabilities | 2.01 | 1.38 |
| Total liabilities | 10.84 | 11.17 |
| Fixed assets | 2.12 | 2.18 |
| CWIP | 1.01 | 1.25 |
| Investments | 0.07 | 0.07 |
| Other assets | 7.64 | 7.67 |
| Total assets | 10.84 | 11.17 |
As reported by the company. Total assets equal total liabilities by construction.
Clinitech Laboratory Ltd cash flow
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operations | -0.88 | -0.79 |
| Cash from investing | -0.73 | -0.68 |
| Cash from financing | 3.98 | 0.51 |
| Net cash flow | 2.37 | -0.96 |
| Free cash flow | -1.73 | -1.60 |
| CFO / operating profit | -87% | -59% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Clinitech Laboratory Ltd operating ratios
| Per year | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | — | 7.20% |
| Debtor days | 68.30 | 71.15 |
| Cash conversion cycle | 68.30 | 71.15 |
| Working capital days | 114.42 | 158.85 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Clinitech Laboratory Ltd shareholding pattern
Promoters held 64.21% at Mar 2026, up from 61.58% at Sep 2024. FIIs 0.32%.
| % held | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoters | 61.58% | 61.58% | 62.42% | 64.21% |
| FIIs | 0.32% | 0.32% | 0.32% | 0.32% |
| Public | 38.11% | 38.11% | 37.27% | 35.49% |
| No. of shareholders | 346 | 303 | 303 | 297 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Clinitech Laboratory Ltd corporate filings
- Certificate under Reg 74(5) of SEBI (DP) Regulations for the quarter ended September 30, 2026Company Updatelow impact
- Closure of Trading Window for Insiders the company from Thursday, October 01, 2026 for Unaudited Standalone & Consolidated Financial Results for thr half yera ended September 30, 2026. ....Insider Trading / SASTlow impact
- Clinitech Laboratory Limited Announces Successful Conclusion of 16th Annual General Meeting and Approval of All ResolutionsAGM/EGMlow impact
Cruxal's analysis: Clinitech Laboratory Limited has successfully concluded its 16th Annual General Meeting…
Read the full analysis - Clinitech Laboratory Limited Concludes 16th Annual General Meeting; No Material Strategic Shifts ReportedAGM/EGMlow impact
Cruxal's analysis: Clinitech Laboratory Limited has successfully concluded its 16th Annual General Meeting…
Read the full analysis - Clinitech Laboratory Ltd schedules Annual General Meeting for September 24, 2026Company Updatelow impact
Cruxal's analysis: Clinitech Laboratory Ltd has issued a newspaper advertisement regarding its upcoming…
Read the full analysis - Clinitech Laboratory Limited Announces 16th Annual General Meeting and Book Closure DatesCorp. Actionlow impact
Cruxal's analysis: Clinitech Laboratory Limited has formally intimated the schedule for its 16th Annual…
Read the full analysis - Clinitech Laboratory Limited Announces Annual General Meeting and Seeks Shareholder Approval for Financial Assistance to SubsidiariesOthersmedium impact
Cruxal's analysis: Clinitech Laboratory Limited has scheduled its 16th Annual General Meeting for September…
Read the full analysis - Clinitech Laboratory Limited announces board approval for 16th Annual General Meeting and routine corporate governance mattersBoard Meetinglow impact
Cruxal's analysis: Clinitech Laboratory Limited has announced the outcome of its board meeting held on…
Read the full analysis - Clinitech Laboratory Limited schedules Board Meeting for August 17, 2026, to finalize 16th AGM and FY 2025-26 Board ReportBoard Meetinglow impact
Cruxal's analysis: Clinitech Laboratory Limited has issued an intimation for a Board of Directors meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.